Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1223 | Difficulties lived by disabled children's parents in the period of COVID-19 pandemic Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009136 | Muscular Dystrophies NIH | 0.71 |
| D002547 | Cerebral Palsy NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003560 | Muscular dystrophy HPO | 0.71 |
| HP:0001264 | Spastic diplegia HPO | 0.58 |
Navigate: Correlations HPO
There is one clinical trial.
In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.
Description: To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD.
Measure: mobidity discharge Time: 0 days after hospitalizationDescription: To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD.
Measure: mobidity at 30 days Time: 30 days after hospitalizationDescription: To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD.
Measure: mobidity 1 year after hospitalization Time: 1 year after hospitalizationDescription: To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD.
Measure: mortality discharge Time: 0 days after hospitalizationDescription: To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD.
Measure: mortality 30 days after hospitalization Time: 30 days after hospitalizationDescription: To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD.
Measure: mortality 1 year after hospitalization Time: 1 year after hospitalizationDescription: Clinical outcomes according to medication at admission evaluated at hospital discharge
Measure: Clinical outcomes according to medication at admission Time: 0 days after hospitalizationDescription: Clinical outcomes according to medication at admission evaluated 30 days after hospitalization
Measure: Clinical outcomes according to medication at admission Time: 30 days after hospitalizationDescription: 1 year after hospitalization
Measure: Clinical outcomes according to medication at admission Time: 1 year after hospitalizationDescription: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge
Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission Time: 0 days after hospitalizationDescription: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 30 days after hospital discharge
Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission Time: 30 days after hospitalizationDescription: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 1 year after hospitalization
Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission Time: 1 year after hospitalizationDescription: New onset of CVD induced by COVID-19 disease at discharge
Measure: New onset of CVD induced by COVID-19 disease Time: 0 days after hospitalizationDescription: New onset of CVD induced by COVID-19 disease evaluated 30 days after hospitalization
Measure: New onset of CVD induced by COVID-19 disease Time: 30 days after hospitalizationDescription: New onset of CVD induced by COVID-19 disease at discharge evaluated 1 year after hospitalization
Measure: New onset of CVD induced by COVID-19 disease Time: 1 year after hospitalizationDescription: Cost of hospital stay
Measure: Cost of hospital stay Time: 0 days after hospitalizationDescription: Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Measure: Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). Time: 30 days after hospitalizationDescription: Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Measure: Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis). Time: 1 year after hospitalizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports